Search
Aclidinium
go.drugbank.com/drugs/DB08897ApprovedAclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). … It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
INO-4800
go.drugbank.com/drugs/DB15693Investigational[A214475] A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. … [A214475, A214478] Follow up studies in both BALB/c mice and Hartley guinea pigs demonstrated the ability of INO-4800 to induce both humoral and T cell-mediated immunity against SARS-CoV-2, including in
Butenafine
go.drugbank.com/drugs/DB01091ApprovedIn particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes. … Butenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols.
Reboxetine
go.drugbank.com/drugs/DB00234ApprovedInvestigationalWithdrawnReboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. … Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.
Probenecid
go.drugbank.com/drugs/DB01032ApprovedInvestigationalProbenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. … It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate.
Categories: Compounds used in a research, industrial, or household settingQuinidine barbiturate
go.drugbank.com/drugs/DB01346ApprovedA papulopurpuric eruption in a patient (without thrombopenia) can be developed who is taking quinidine phenylethyl barbiturate intermittently and at reintroduction.(PMID: 9739909)
Zinc dibutyldithiocarbamate
go.drugbank.com/drugs/DB14194ApprovedZinc dibutyldithiocarbamate is a dermatological sensitizer and allergen. Sensitivity to zinc dibutyldithiocarbamate may be identified with a clinical patch test.
Mantle Cell Lymphoma (MCL)
go.drugbank.com/conditions/DBCOND0071979Synonyms: Mantle zone lymphoma, Mantle zone lymphoma [obs]Methaqualone
go.drugbank.com/drugs/DB04833ApprovedIllicitWithdrawnThe sedative-hypnotic activity was first noted by Indian researchers in the 1950s and in 1962 methaqualone itself was patented in the US by Wallace and Tiernan. … Methaqualone is a sedative-hypnotic drug that is similar in effect to barbiturates, a general central nervous system depressant.
PRO 2000
go.drugbank.com/drugs/DB05385InvestigationalPRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. … It is being studied for the prevention of HIV infection and other sexually transmitted diseases.
Categories: Compounds used in a research, industrial, or household setting